Back to Top Skip to main content

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

Measles Myths: The Measles Can Be Life-Threatening

Video
9/30/2019
Measles Myths: The Measles Can Be Life-Threatening

Measles can be life-threatening, especially for children and among people who have a compromised immune system.

Recommended Content:

Preventive Health | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella

Measles Myths: Hand Washing Alone Won't Prevent Measles

Video
9/23/2019
Measles Myths: Hand Washing Alone Won't Prevent Measles

Hand washing alone will not prevent the spread of measles. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Preventive Health | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella

Measles Myths: Vaccines Are Safe

Video
9/17/2019
Measles Myths: Vaccines Are Safe

Vaccine components have been rigorously tested for safety. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Preventive Health | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella

Measles Myths: Vaccines Do Not Cause Autism

Video
9/12/2019
Measles Myths: Vaccines Do Not Cause Autism

Vaccines that prevent measles do not cause autism. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Preventive Health | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella | Autism Care Demonstration

Prevent to Protect: Analia

Video
8/30/2019
Prevent to Protect: Analia

Cancer left 5-year-old Analia Pages unable to get vaccinated. Her father, Master Sgt. Edward Pages, has to take extra steps to protect her from diseases she’s susceptible to.

Recommended Content:

Immunization Healthcare | Preventive Health | Immunizations

Prevent to Protect: Rosarios

Video
8/30/2019
Prevent to Protect: Rosarios

10-year-old Tatiana Rosario has a weakened immune system as a result of her cancer treatment. Growing up, she and her family made sacrifices to keep her safe from disease.

Recommended Content:

Immunization Healthcare | Preventive Health | Immunizations

Prevent to Protect: Immunization Awareness

Video
8/30/2019
Prevent to Protect: Immunization Awareness

Getting vaccinated not only protects yourself and your family from deadly diseases, but it also saves the lives to those who don’t have the immune system to fend for themselves. The Military Health System shares the stories of families with children who are at risk when others aren’t immunized.

Recommended Content:

Immunization Healthcare | Preventive Health | Immunizations

Prevent to Protect: Barbara and Floriann

Video
8/30/2019
Prevent to Protect: Barbara and Floriann

Barbara’s son Floriann grew up with an immune dysregulation. A Uniformed Services University pathology professor, she’s experienced first hand the importance of vaccines.

Recommended Content:

Immunization Healthcare | Preventive Health | Immunizations

How The U.S. Military Is Contributing To The Fight Against Cholera In Mozambique

Video
4/16/2019
Air Force Capt. Talon Miner, a flight surgeon assigned to the 435th Contingency Response Group, Ramstein Air Base, Germany, supporting Combined Joint Task Force-Horn of Africa, discusses the role that the U.S. Department of Defense is undertaking to combat the spread of Cholera in Mozambique.

Air Force Capt. Talon Miner, a flight surgeon assigned to the 435th Contingency Response Group, Ramstein Air Base, Germany, supporting Combined Joint Task Force-Horn of Africa

Recommended Content:

Global Health Engagement | Global Health Security Agenda | Building Partner Capacity and Interoperability | Humanitarian Assistance and Disaster Relief

Bringing Comfort 2018

Video
10/17/2018
The USNS Comfort is a state-of-the-art hospital ship, and it’s scheduled to deploy to Central and South America for Continuing Promise 2018.

The USNS Comfort is a state-of-the-art hospital ship, and it’s scheduled to deploy to Central and South America for Continuing Promise 2018.

Recommended Content:

Global Health Engagement | Global Health Engagement

Exercise Immediate Response 16

Video
1/13/2017
Soldiers and Airmen practice combat trauma care with allied and partner nation medical service members at Cerklje ob Krki, Slovenia, as part of exercise Immediate Response.

Soldiers and Airmen practice combat trauma care with allied and partner nation medical service members at Cerklje ob Krki, Slovenia, as part of exercise Immediate Response.

Recommended Content:

Health Readiness | Global Health Engagement

A human vaccine for the Zika virus may be coming soon

Video
7/22/2016
Scientists at the Walter Reed Army Institute of Research in Silver Spring, Maryland, have developed a vaccine for the Zika virus. They received a strain of the virus from Puerto Rico in November 2015, and have since created a purified inactivated virus, like the flu shot. The vaccine is called ZPIV, and so far, it looks promising that military medical research will be a key contributor to preventing the continued spread of the Zika virus.

Scientists at the Walter Reed Army Institute of Research in Silver Spring, Maryland, have developed a possible vaccine for the Zika virus.

Recommended Content:

Mosquito-Borne Illnesses | Zika Virus | Immunization Healthcare | Medical Research and Development

How is the U.S. Military Dealing with Zika?

Video
6/7/2016
Zika image

The Defense Department is closely monitoring the spread of the Zika virus and is working with the Centers for Disease Control and Prevention to assist in virus surveillance, response and research efforts.

Recommended Content:

Zika Virus | Global Health Engagement | Mosquito-Borne Illnesses
Showing results 1 - 13 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.